Predicting response, improving patient outcome

Posted on: Friday, May 29th, 2015

Scott Clark, VP of Global Scientific Operations speaks about Cancer Genetics’ PGx services and how CGI is at the forefront of personalized medicine.

Individuals respond differently to medications based on their genetic profile. For oncology medications, it is extremely important to understand the underlying genetics for safety and efficacy purposes.

Pharmacogenomics can help reduce adverse effects as well as predict efficacy of certain medications.  Cancer Genetics offers a comprehensive testing package to help predict patient outcome and aid in drug development. For oncologist, such genomic insight can help in patient management whereas it can help Biopharma companies during drug development.

Helping patient get the right therapy is essential to Cancer Genetics’ work.  Cancer Genetics’ pharmacogenomics services puts the company at the forefront of personalized medicine.

Filed Under:

> Additional Articles
> Join Our Mailing List

Additional Videos»

  • Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®

    The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for  KEYTRUDA® (pembrolizumab)​ is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer

  • Cancer Genetics is a center of excellence for oncology-focused clinical trials.

    Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges. The current challenge that is faced by biotech and biopharmas that are involved in oncology drug development is their ability to accurately stratify and randomize patients for their clinical trials based on biomarkers. Despite the […]

  • Cancer Genetics offers an integrated solution for clinical trials.

    Kristen Hopp, PMP, Senior Clinical Trial Project Associate speaks about Cancer Genetics integrated clinical trial services. In hematological malignancies one of the challenges is the diversity of subtypes.  For these trials, genomic insights have become critically important.  Our innovative research and our clinical expertise in these cancers makes CGI an ideal partner for these clinical […]

  • Cancer Genetics offers an integrated solution for Clinical Trials.

    Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important. As a clinical trial progresses and a more diverse patient population is recruited, variations in a drug’s efficacy and safety can start to arise. Unexpected adverse events can potentially kill a drug at […]

See All Videos Back to Top